Epilepsy

Take a look back at some of the most-viewed, top video series with key experts in neurology and their in-depth discussions, part of NeurologyLive®'s Year in Review.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jennifer Majersik, MD, MS.

As part of NeurologyLive®'s Year in Review, take a look at some of the most engaging conversations the team has had with experts in neurology this past year.

As part of NeurologyLive®'s Year in Review, take a look at some of the most listened to and engaging conversations from the Mind Moments™ podcast from this past year.

As part of NeurologyLive®'s Year in Review, take a look at some of the biggest FDA approvals and decisions from this past year.

As part of NeurologyLive®'s Year in Review, take a look at some of the best features that have been published on the site this year.

Here's what is coming soon to NeurologyLive®.

Take a look back at some of the most top video interviews with key experts in neurology and their insights and perspectives on topics in neurology subspecialties, as part of NeurologyLive®'s Year in Review.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 24, 2021.

These news stories led the pack in conversations in the field of epilepsy and were often included in NeurologyLive®'s coverage of seizure disorders.

Darcy Krueger, MD, PhD, director, Tuberous Sclerosis Clinic, Cincinnati Children’s, provided insight on a new trial that aims to stop the onset and progression of tuberous sclerosis complex.

As Dravet syndrome is often nonresponsive to existing therapeutics, it can be a challenge to treat, and this refractory nature creates a great need for novel, innovative, and safe antiepileptic drugs for its treatment.

Here's what is coming soon to NeurologyLive®.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, provided context on improving our use of current antiseizure medications as the top priority for patients with epilepsy. [WATCH TIME: 2 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 17, 2021.

The director of the epilepsy center at Cleveland Clinic Neurological Institute spoke on one of the studies he coauthored that were presented at AES 2021. [WATCH TIME: 4 minutes]

The director of the Tuberous Sclerosis Clinic at Cincinnati Children’s provided insight on promising drug developments for tuberous sclerosis complex and other notable priorities within the space.

The director of Cleveland Clinic’s Epilepsy Center at the Cleveland Clinic Neurological Institute discussed the need for specificity and artificial intelligence for patients with epilepsy. [WATCH TIME: 4 minutes]

Jessica Fesler, MD, MEd, staff epileptologist, Cleveland Clinic, offered insight on the future of seizure apps and how if improved, they could alter the treatment of patients with epilepsy.

The medical director of the Epilepsy program at the University of Toronto discussed her presentation at AES 2021 regarding the need to change how clinicians view and treat patients with developmental epileptic encephalopathies.

Here's what is coming soon to NeurologyLive®.

The director of the Tuberous Sclerosis Clinic at Cincinnati Children’s discussed the phase 2 open-label study of ganaxolone in TSC and whether drug development remains the top priority for these patients. [WATCH TIME: 3 minutes]

Neurology News Network for the week ending December 11, 2021. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 10, 2021.

The director of Cleveland Clinic’s Epilepsy Center at the Cleveland Clinic Neurological Institute spoke on the latest advances with epilepsy surgery, as well as what still needs to be learned. [WATCH TIME: 5 minutes]

Leaders in the epilepsy space provided their thoughts on the most promising aspects, initial takeaways, and dominating conversations at the 2021 American Epilepsy Society annual meeting.

Adverse effects were common but manageable among patients and were not identified as a reason to discontinue treatment in those with refractory disease.

The director of Cleveland Clinic’s Epilepsy Center at the Cleveland Clinic Neurological Institute discussed poignant presentations from the 2021 American Epilepsy Society Annual Meeting. [WATCH TIME: 7 minutes]

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed numerous presentations from AES 2021 that bolstered cenobamate’s known efficacy and safety profile. [WATCH TIME: 7 minutes]

Investigators suggest further studies to better determine is NPC had measurable benefits for patient quality of life.